Molecular abnormalities of the B cell in systemic lupus erythematosus are candidates for functional inhibition treatments

Author： Liossis Stamatis-Nick C   Melissaropoulos Konstantinos  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.15, Iss.6, 2014-04, pp. : 833-840

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

B-Cell-Targeted Therapy for Systemic Lupus Erythematosus

By Sabahi Ramin   Anolik Jennifer H.  

Drugs, Vol. 66, Iss. 15, 2006-01 ,pp. : 1933-1948

Adis International

Access to resources Recommend Favorite

B cell depletion in systemic lupus erythematosus

By Leandro Maria J   Ehrenstein Michael R  

Clinical Medicine, Vol. 7, Iss. 1, 2007-01 ,pp. : 57-59

Royal College Of Physicians

Access to resources Recommend Favorite

Novel Molecular Targets for Systemic Lupus Erythematosus

By  

Current Drug Targets, Vol. 3, Iss. 3, 2002-06 ,pp. : 223-228

Bentham Science Publishers

Access to resources Recommend Favorite

Signaling Abnormalities in Systemic Lupus Erythematosus as Potential Drug Targets

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 6, Iss. 4, 2006-12 ,pp. : 305-311

Bentham Science Publishers

Access to resources Recommend Favorite

Novel Molecular Targets for Systemic Lupus Erythematosus and Other Immune-Complex and T-Cell Mediated Autoimmune Diseases - Update

By  

Medicinal Chemistry Reviews - Online, Vol. 1, Iss. 3, 2004-07 ,pp. : 331-332

Bentham Science Publishers

Access to resources Recommend Favorite